chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Paroniod jittery feeling; Paroniod jittery feeling; This is a spontaneous report from a contactable consumer, the patient. A 60-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: en6199) via an unspecified route of administration in the left arm on 08Mar2021 at 13:00 (at the age of 60-year-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. The patient had no known allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included hormones (unspecified) from an unknown date for an unknown indication and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. On 10Mar2021 at 10:00, the patient experienced paranoid jittery feeling. Therapeutic measures were not taken as a result of the events. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event paranoid jittery feeling was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Welts on the back of tongue. Swollen papillae. Blister sized lumps. Painless but seem to be increasing in size
Patient received Moderna 0.25ml  booster instead of Pfizer 0.3ml booster
stomach cramps; dizziness; axillary lymph node enlargement and pain; Fever 102; body aches; severe chills; joint pain; headache; nausea; axillary lymph node enlargement; local site reaction/pain; local site reaction/pain; This is a spontaneous report from a contactable healthcare professional, the patient.  A 58-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8727) via an intramuscular route of administration in the left arm on 25Mar2021 at 09:00 (at the age of 58-years-old) as a single dose for COVID-19 immunisation. Medical history included hypertension and hypothyroidism. Concomitant medications included HCTZ (hydrochlorothiazide) (MANUFACTURER UNKNOWN), Withania somnifera (ASHWAGANDHA), levothyroxine (MANUFACTURER UNKNOWN), losartan (MANUFACTURER UNKNOWN), multivitamin (MANUFACTURER UNKNOWN) and melatonin (MANUFACTURER UNKNOWN), all for unknown indications from unknown dates. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6202), via an intramuscular route of administration in the left arm on 04Mar2021 at 09:00 (at the age of 58-years-old) as a single dose for COVID-19 immunisation. The patient previously received morphine (MANUFACTURER UNKNOWN) and experienced drug allergy. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 25Mar2021 at 19:00, the patient experienced fever 102, severe chills, body aches, joint pain, headache, nausea, stomach cramps, dizziness, local site reaction/pain, and axillary lymph node enlargement and pain. The symptoms began 10 hours post injection and lasted 48 hours. The patient did not receive any treatment for events fever, chills, general body pain, joint pain, headache, nausea, stomach cramps, dizziness, axillary lymph nodes enlarged, vaccination site pain, vaccination site reaction and lymph node pain. The clinical outcomes of the events fever, chills, general body pain, joint pain, headache, nausea, stomach cramps, dizziness, axillary lymph nodes enlarged, vaccination site pain, vaccination site reaction and lymph node pain were recovered on 27Mar2021 at 19:00.   No follow-up attempts are needed. No further information is expected.
patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion); patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion); This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) in a 51-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported.  Reporter stated that no adverse reactions were reported by any patients.  No treatment medications were reported.
This spontaneous report was received from a medical assistant refers to a patient of unknown age and gender. On 12-AUG-2014, the patient was vaccinated with GARDASIL (0.5 ml, lot# J011272, expiration date: 21-APR-2016) intramuscularly which underwent a temperature excursion. No adverse events were reported. At the time of the report action taken with GARDASIL was unknown. This is one of several reports from the same source. Additional information has been requested.
patient immediately got light headed and basically passed out, unresponsive, nauseousness and belching
PAIN IN ARM; UPSET STOMACH; This spontaneous report received from a patient concerned a 54 year old of unspecified sex. The patient's weight, height, and medical history were not reported.The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1805025, expiry: 25/AUG/2021) dose was not reported, administered on 19-MAR-2021 for prophylactic vaccination. No concomitant medications were reported. On 19-MAR-2021, the subject experienced pain in arm. On 19-MAR-2021, the subject experienced upset stomach. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from pain in arm on 21-MAR-2021, and upset stomach on 20-MAR-2021. This report was non-serious.
Narrative: Per nurse's report, patient complained of felling "tired, weak, and cold" for 2-3 days after receiving Moderna COVID booster
Initial case received via search of scientific literature on 26 July 2012. The following is verbatim from the article abstract: "Objective: In 2010, an area experienced the highest number of pertussis cases in >60 years, with >9000 cases, 809 hospitalizations, and 10 deaths. This report provides a descriptive epidemiologic analysis of this epidemic and describes public health mitigation strategies that were used, including expanded pertussis vaccine recommendations. STUDY DESIGN: Clinical and demographic information were evaluated for all pertussis cases with onset from January 1, 2010 through December 31, 2010, and reported to the Department of Public Health. RESULTS: Infants younger than 6 months had the highest disease rates; all deaths and most hospitalizations occurred in infants younger than 3 months. Most pediatric cases were vaccinated according to national recommendations, although 9% of those aged 6 months to 18 years were completely unvaccinated against pertussis. High disease rates also were observed in fully vaccinated preadolescents, especially 10-year-olds. Mitigation strategies included expanded tetanus, diphtheria, and acellular pertussis vaccine recommendations, public and provider education, distribution of free vaccine for postpartum women and contacts of infants, and clinical guidance on diagnosis and treatment of pertussis in young infants. CONCLUSIONS: Infants too young to be fully vaccinated against pertussis remain at highest risk of severe disease and death. Data are needed to evaluate strategies offering direct protection of this vulnerable population, such as immunization of pregnant women and of newborns. The high rate of disease among preadolescents suggests waning of immunity from the diphtheria, tetanus, and acellular pertussis series; additional studies are warranted to evaluate the efficacy and duration of protection of the diphtheria, tetanus, and acellular pertussis series and the tetanus, diphtheria, and acellular pertussis series." The following is verbatim from the article: "The remaining fatality was a 2-month-old infant born prematurely at 28 weeks gestational age who had received the first dose of diphtheria, tetanus, and accelular pertussis (DTaP) vaccine 15 days prior to disease onset." A two-month-old infant (date of birth and gender not reported), who was born at 28 weeks gestation, received dose one injection of DTaP, manufacturer unknown, (lot number, route and site not reported) on an unspecified date. On an unspecified date, 15 days after vaccination, the patient developed Pertussis. Other than premature birth, the patient's past medical history, concomitant medications or vaccinations were not reported. Hospitalization, laboratory/diagnostic studies, treatments and date of death were not reported. The patient's outcome was reported as fatal. Documents held by sender: None.
A few days after I received my 7th Anthrax shot. I had swelling and pain in my knees and hip joints. After returning from deployment I seen a orthopedic and had a bone density scan and x-rays. He diagnosed me with osteoarthritis. Symptoms have decreased over this time.
Streaks of blood in stool starting 10-8-09 X 3 days.  Abdominal discomfort.  Blood in stool again 10-13-09.
Roughly a week after getting the second dose, I got severe nerve pain in my left thigh that feels like lightning eminating through my leg. My hands and feet are constantly cold to the point of sharp pain, as I can tell my circulation is now horrible from this poison that was forced on me at threat of my job that allows me to support my 4 kids. I also started having HORRIFYING tremors a couple of weeks after the vaccine that feel like seizures while being completely conscious and feeling all of the pain. My hands, feet, legs, traps, (all muscles basically) go into severe cramps with shaking, curling and extreme pain. I also have developed pains in my heart shortly after vaccination that horrify me given the number of people dropping dead suddenly in my same demographic. This is the scariest thing that's ever happened to me in my life - and that is saying something coming from me. I need the system to actually work here and make this right. This is horrible and I feel totally helpless.
Muscle aches, swollen lymph nodes, pain in joints, and extremely tired.  Rest, drank a lot of fluids and took Tylenol 500mg PRN
High fever, hallucinations, myalgias began 2-3 hrs after administration. No other problems. It lasted 24-36 hours.
PATIENT RECIEVED WRONG DOSIS DUE TO ERROR VACCINE ADMINISTRATION. HE WAS ONLY DUE FOR MMR, VARICELLA AND FLU. PATIENT WAS PLACED ON OBSERVATION FOR 15 MINUTES, ADVISED PARENT TO OBSERVE PATIENT  AND IF ANY REACTION PLEASE TAKE PATIENT TO EMERGENCY ROOM.  PATIENT TOLERATED VACCINE WELL NO REACTIONS ON THE TIME OF OBSERVATION.
postherpetic neuralgia; herpes zoster; Information has been received from a lawyer regarding a case in litigation and referring to a female patient (pt) of unknown age. Information about the pt's concurrent conditions, medical history and concomitant medications was not reported. On an unknown date, the pt was inoculated with zoster vaccine live (ZOSTAVAX) (dose, route of administration, anatomical location, lot # and expiration date were not reported) for routine health maintenance and for its intended purpose: the prevention of shingles (herpes zoster). On an unknown date, reported as after receiving zoster vaccine live (ZOSTAVAX), the pt suffered herpes zoster and postherpetic neuralgia. As a result of these symptoms, the pt was seen and treated by medical providers and at the time of report was still under their care. As a direct and proximate result of the defective zoster vaccine live (ZOSTAVAX) vaccine, the pt's symptoms had resulted in physical limitations not present prior to using the suspect product. The pt also experienced mental and emotional distress due to resulting physical limitations and seriousness of the pt's condition. As a result of the manufacture, marketing, advertising, promotion, distribution and/or sale of zoster vaccine live (ZOSTAVAX), the pt sustained severe and permanent personal injuries. Further, as a tragic consequence of the zoster vaccine live (ZOSTAVAX), the pt suffered serious, progressive, permanent, and incurable injuries, as well as significant conscious pain and suffering, mental anguish, emotional distress, loss of enjoyment of life, physical impairment and injury. As a direct and proximate result of zoster vaccine live (ZOSTAVAX), the pt had suffered and incurred damages, including medical expenses; the loss of accumulations; and other economic and non-economic damages. The outcome of the events was not recovered. The reporter considered the events to be related to zoster vaccine live (ZOSTAVAX).  The events of herpes zoster and postherpetic neuralgia were considered to be disabling.
3-4 cm area of induration (redness, warmth, firm nodule), itching, bruising 24 hours after injection lasting > 7 days.
Grandma reported to office Rash only all over body that lasted 3-4 days. She reported it to the office on 7/11/23.  Patient was not seen for adverse effect because Grandma never called office. She reported the event when she seen me in the office at another visit for the patient's sibling on 7/11/23. She said he had a rash for 3-4 days, and that he was better.
24 hours after injection developed pain in back that spread to L arm, under arm and down Left arm. Numbness in Left habd for 5 mins on 2 nites. Had dizziness and disorientation 2 days after injection. Still having pain in arm.
This is patients second pregnancy.  Her due date is 11/19/21.  She came in today complaining of intense uterine contractions that felt like tightening and period cramps and were causing intense vaginal pressure.  This pain had been occurring every 2-10 minutes for almost 24 hours, it was so bad she could not sleep.   According to the TOCO monitor and my assessment she was not contracting.  The fetal heart rate was appropriate for the gestational age.  Her cervix was not dilated or effaced.  She was not bleeding or leaking fluid and the baby was active.
Information has been received from a registered nurse concerning a 3 year old female with no known drug allergies and no pertinent medical history, who on 28-JUL-2008 was vaccinated with VARIVAX (Merck) (lot # 652873/0433F), 0.5 mL, subcutaneously. On approximately 10-AUG-2008 (3 days ago) after receiving her first and only dose, the patient experienced chickenpox. The patient had more than 50 lesions all over the body including in her throat inside of her mouth. Most of the lesions were either fluid filled or scabbed. The physician saw the patient. At the time of reporting, the patient was recovering. Additional information has been requested.
Large red circular welt at injection site that is very firm and hot to the touch. Redness keeps spreading each day.  24 hours post injection, patient started feeling nauseous and vomiting excessively. It is now 36 hours post injection and patient is still vomiting and feeling ill.
PT REPORTED PAIN AT SITE OF INJECTION FOR FIRST COUPLE DAYS, THEN REPORTED SPASMS AND MUSCLE PAIN THAT LIMITS MOVEMENT.
I had a sleepy or numbness, tingly in that arm, from 40-45 secs. at a time, It does not happen as frequently as it does now, it used to be several times a day.
painful axial lymph nodes on same side as injection; painful axial lymph nodes on same side as injection; plantar fasciitis flare up; booster; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 53 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 20Nov2021 12:30 (Lot number: FH8028) at the age of 53 years as dose 3 (booster), single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (Dose Number: 2, Batch/Lot No: ER8737, Location of injection: Arm Left, Vaccine Administration Time: 09:30 AM), administration date: 03Apr2021, when the patient was 53 years old, for Covid-19 immunization; Bnt162b2 (Dose Number: 1, Batch/Lot No: EN6204, Location of injection: Arm Left, Vaccine Administration Time: 08:00 AM), administration date: 11Mar2021, when the patient was 53 years old, for Covid-19 immunization. The following information was reported: IMMUNISATION (non-serious) with onset 20Nov2021 12:30, outcome "unknown", described as "booster"; LYMPH NODE PAIN (non-serious), AXILLARY PAIN (non-serious) all with onset 21Nov2021 20:00, outcome "not recovered" and all described as "painful axial lymph nodes on same side as injection"; PLANTAR FASCIITIS (non-serious) with onset 21Nov2021 20:00, outcome "not recovered", described as "plantar fasciitis flare up". Therapeutic measures were not taken as a result of lymph node pain, axillary pain, plantar fasciitis.  Additional information: The most recent COVID-19 vaccine was administered in public health clinic/veterans administration facility. The patient had not received any other vaccine within 4 weeks prior to the covid vaccine. Patient had not been diagnosed with COVID-19 prior to vaccination and had not been tested since the vaccination. The patient had No known allergies.  Follow-up attempts are completed. No further information is expected.
Pt stated that on 11NOV93 began having h/a & pain & weakness to rt hip & leg; sx progressed so on 16NOV93 went to MD c/o h/a, muscle-tension or migraine; r/o brain tumor; rt leg pain; due to lumbar radiculopathy; elevated BP;
This spontaneous report was received from a physician via company representative referring to a patient of unknown age and gender. The patient's medical history, drugs reactions or allergies, concurrent conditions and concomitant therapies were not reported. On 27-APR-2016, the patient was vaccinated with a dose of improperly stored RECOMBIVAX HB. "10 PK 0.5 mcg/0.5ml SDLLolCap Ped" and lot number L023387 with expiration date of 22-JUN-2017 (route and anatomical location of administration were not reported). The vaccine had two temperature excursions one of 24 hours with a lowest recorded temperature of 49 Fahrenheit (F) (9.444444444 C). The storage criteria and the storage type were reported as "Refrigerator(R)". The vaccine status was reported as "in excursion". No adverse effects were reported nor Product Quality Complaint (PQC) was involved. This is one of several cases from the same reporter. Additional information has been requested.
Experienced a low grade fever; body aches; This is a spontaneous report from a non-contactable consumer. A 34-year-old non-pregnant female patient received the second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; lot number and expiry date: not reported), via an unspecified route of administration on 24Jan2021 at 10:30 at a single dose on the right arm for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. The patient previously took first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) on an unspecified date for COVID-19 immunization. The patient was not diagnosed with COVID-19 prior to vaccination. Last Monday (25Jan2021), the patient experienced a low grade fever and body aches. The patient did not receive any treatment for the reported events. Since the vaccination, the patient has not been tested for COVID-19. The outcome of the events was recovered on 26Jan2021.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
About two weeks following my second dose of vaccine, my hearing in the left ear became increasingly diminished over several days. I consulted with  an ENT physician for examination and hearing test. Hearing found to be around 30% in left ear compared to baseline three years earlier at 96%. Right ear nearly 100%. Left ear treated with steroid injections once weekly for two weeks. Hearing test repeated one week following the second steriod treatment. Left ear hearing was back to about 96% at that time.
10-15 minutes after getting the vaccines pt cough, and developed a wheal like rash faintly on the arms and face. EMS was called and pt was taken to the ER. Pt alert and in no acute distress. ER called and DR in ER stated Pt was doing well. Pt received Epinephrine and Benadryl and rash is resolved, pt will be discharged home.
This spontaneous report was received from a Registered Nurse (RN) and refers to an unknown amount of patients (ages and gender unknown). Medical history and concomitant medications were not provided. On an unspecified date, the patients received PNEUMOVAX 23. The RN reported that the vaccine underwent temperature excursion on 27-JUN-2017 and an unknown number of patients may have been vaccinated with this product. Total time in the range of 47 degrees F to 77 degrees F: 47.1 degrees F for six minutes. A data logger was involved. Lot numbers and expirations dates were as follows: 7 vials: M026317; expiration 11-JAN-2018; 10 vials: M029681; expiration 22-JAN-2018; 10 vials: M047519; expiration 04-JUL-2018. The outcome was unknown. Additional information has been requested.
Inflamed and in a lot of pain all over my body, in the general area where I have polymyalgiarumaticia  flare ups, but it's a bad flare up.